03/09/2025
Version A: Neutral, concise
We may have a potential cure for diabetes.
A patient with type 1 diabetes is producing his own insulin after receiving a groundbreaking transplant of gene-edited pancreatic cells, without needing anti-rejection drugs.
This marks the first time in humans that donor islet cells have been genetically modified to evade the immune system entirely.
Type 1 diabetes occurs when the immune system mistakenly attacks the islet cells in the pancreas, which are responsible for insulin production.
Treatments typically involve lifelong insulin injections and, in some cases, transplants, though these often require immunosuppressants, which carry long-term risks. In this new case, a 42-year-old man who had lived with type 1 diabetes since childhood received injections of donor islet cells into his forearm. Before that, scientists made three specific edits using CRISPR: two removed cellular markers that help T cells recognize foreign tissue, and one added a protein called CD47 to help block the body's innate immune responses.
The results were striking. Over 12 weeks, the edited cells began producing insulin in response to glucose spikes, such as after meals. The man did not require immunosuppressive medication to keep the cells alive. Not all edited cells survived; only those with all three edits remained functional, which provided a built-in comparison and proof that the editing approach could work. While the patient did not receive enough cells to fully manage his condition without additional treatment, the experiment shows that functional, gene-edited cell transplants can survive and function in the human body without being attacked by the immune system.
Paper: "Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression," New England Journal of Medicine (2025)
Version B: More cautious, with emphasis on novelty
There is potential progress toward a cure for diabetes.
A patient with type 1 diabetes is producing his own insulin after receiving a pioneering transplant of gene-edited pancreatic cells, without anti-rejection drugs.
This represents the first human demonstration of donor islet cells engineered to evade the immune system entirely.
Type 1 diabetes arises when the immune system mistakenly attacks the islet cells in the pancreas, which produce insulin.
Conventional treatments often require lifelong insulin injections and, in some cases, transplants that rely on immunosuppressants with notable risks. In this study, a 42-year-old man who has had type 1 diabetes since childhood received injections of donor islet cells into his forearm. Scientists implemented three CRISPR edits: two removed cellular markers that help T cells recognize foreign tissue, and one added CD47, a protein that can help shield cells from certain innate immune responses.
The observed effects were notable. Over 12 weeks, the edited cells began to secrete insulin in response to glucose changes following meals. The patient did not require immunosuppressive therapy to sustain the cells. Not all edited cells persisted; only those with all three edits remained functional, providing a direct comparison and evidence that the editing approach was effective. Although the patient did not receive enough cells to fully control his condition without additional treatment, the study demonstrates that functional, gene-edited cell transplants can survive and function in the human body without immune attack.
Paper: "Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression," New England Journal of Medicine (2025)
